Brief: Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne
04/03/2025 14:16
March 4 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA ANNOUNCES THAT LAST PATIENT COMPLETES LAST VISIT IN PIVOTAL XYNGARI™ PHASE 3 STAR-1 CLINICAL TRIAL FOR ACNE DERMATA THERAPEUTICS INC - TOPLINE DATA EXPECTED BY END OF MARCH 2025 Source text: ID:nPn9Mbslqa Further company coverage: DRMA.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview